Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated September 14, 2026, reports positive registrational data from the phase I/II ARROS-1 trial for Jideytro (zidesamtinib). The data supports a planned supplemental New Drug Application (NDA) to the US FDA in 2026 to expand the drug's indication to first-line treatment for ROS1-positive non-small cell lung cancer (NSCLC). The results were presented at the 2026 World Conference on Lung Cancer in Seoul.
Key Financial and Operational Metrics
The filing focuses on clinical trial efficacy and safety metrics rather than financial performance. No revenue, profit, cash flow, debt, or liquidity figures are provided in this document.
- Objective Response Rate (ORR): 94% (88/94 patients) in TKI-naïve patients.
- Complete Response Rate: 15% (14/94 patients).
- Progression-Free Survival (PFS): 90% at 12 months; median PFS not reached.
- Brain Metastases Response: 100% response rate in patients with measurable brain metastases; 70% achieved complete clearance.
- Safety Profile: Treatment-related adverse events (TRAEs) led to dose reductions in 11% of patients and discontinuation in 1%.
Material Changes and Regulatory Status
Jideytro was approved by the FDA in July 2026 for patients with ROS1-positive NSCLC previously treated with a tyrosine kinase inhibitor (TKI). This filing represents a material development toward expanding that approval to the first-line setting. The data demonstrates durable responses and a differentiated tolerability profile compared to existing challenges in the disease area.
Outlook, Risks, and Management Commentary
Management, including Hesham Abdullah (Global Head of Oncology, R&D), highlighted the potential for zidesamtinib to address unmet needs in long-term disease control and brain metastasis management. GSK plans to submit a supplemental NDA to the FDA in 2026. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2025 Form 20-F and Q2 2026 results.
Key Facts for Investor Verification
- Verify the timeline and status of the supplemental NDA submission to the FDA for first-line indication.
- Confirm the commercial impact of the July 2026 approval for previously treated patients on GSK's oncology revenue.
- Review the full safety data regarding long-term tolerability and specific adverse events (e.g., peripheral oedema, weight increase).
- Assess the competitive landscape for ROS1-positive NSCLC treatments following this data release.
- Check for any updates on the integration of Nuvalent, Inc., the source of the Jideytro asset, into GSK's operations.